Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effect of Noninvasive Ventilation on Physical Activity and Inflammation in COPD Patients

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2013 by Hospital Universitario La Paz
Information provided by (Responsible Party):
Francisco Garcia-Rio, Hospital Universitario La Paz Identifier:
First received: December 22, 2009
Last updated: April 1, 2013
Last verified: April 2013

Parallel, randomized and controlled clinical trial to evaluate the effect of 12 months of noninvasive mechanical ventilation versus conventional treatment in hypercapnic patients with stable COPD.

Main objective: To evaluate the effect of 12 months of noninvasive ventilation on c-reactive protein concentration and daily physical activity in hypercapnic patients with stable COPD.

Secondary objectives: To compare the plasmatic concentration of other inflammatory biomarkers between COPD patients with conventional treatment and wich noninvasive ventilation. To determine the response of breathlessness, health-related quality of life and lung function to noninvasive ventilation. To identify the COPD patients with a higher gasometric and clinic response to noninvasive ventilation.

Condition Intervention Phase
Chronic Obstructive Pulmonary Disease
Drug: Control
Device: NIMV group
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Effect of the Noninvasive Mechanical Ventilation on the Daily Physical Activity and the Inflammatory Biomarkers in Stable Patients With COPD

Further study details as provided by Hospital Universitario La Paz:

Primary Outcome Measures:
  • daily physical activity and plasmatic concentration of C-reactive protein [ Time Frame: 12 months ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Seric concentrations of homocisteine, proBNP, fibrinogen, cholesterol, tg, tnf-alpha, IL-1, IL-6 and 8-isoprostane [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • PaO2, PaCO2, pH, IC, VCIN, FVC, FEV1, FEV1/FVC, TLC, FRC/TLC, RV/TLC,PImax, PEmax, TTmus, 6MWD [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • BDI/TDI, SF-36, SGRQ, LCADL [ Time Frame: 12 months ] [ Designated as safety issue: No ]
  • Adverse effects [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]
  • Cardiovascular effects, exacerbations, hospitalizations and mortality [ Time Frame: 12 months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 50
Study Start Date: December 2009
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Control
Conventional treatment for COPD
Drug: Control
Current treatment according to the ATS/ERS guidelines
Other Name: Bronchodilator agents and inhaled corticosteroids
Experimental: NIMV group
NIMV: Conventional treatment plus noninvasive mechanical ventilation
Device: NIMV group
Current treatment according to the ATS/ERS guidelines and nocturnal BiPAP (IPAP 10-20 cmH2O,EPAP 4-6 cmH2O).
Other Name: Bronchodilator agents and inhaled corticosteroids.


Ages Eligible for Study:   45 Years to 75 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Age: 45-75 yrs.
  • COPD diagnosis (postbronchodilator FEV1/FVC < 0.7) for at least 6 months.
  • FEV1 < 45% predicted
  • Baseline pH 7.35-7.45
  • Baseline PaCO2>45 mmHg breathing current air
  • Smoking history (>15 pack-year)
  • Clinically stable for at least the last three months
  • Pharmacological treatment optimized in the last two years.

Exclusion Criteria:

  • Previous diagnosis of asthma, other airway obstructive disease, sleep apnea syndrome, interstitial lung disease, chest wall disease or neuromuscular disease.
  • Apnea-hypopnea index > 10/h
  • Morbid obesity (BMI > 45 Kg/m2)
  • Previous diagnosis of ischaemic heart disease, cardiac failure, cirrhosis, chronic renal failure, rheumatoid arthritis or other inflammatory disease.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01037387

Contact: María Antonia Gomez-Mendieta, MD 34917277253

Hospital Universitario La Paz Recruiting
Madrid, Spain, 28034
Contact: María Antonia Gómez-Mendieta, MD    917277253   
Principal Investigator: María Antonia Gomez-Mendieta, MD         
Principal Investigator: Claudia Llontop         
Principal Investigator: Francisco Garcia-Rio, PhD         
Sponsors and Collaborators
Hospital Universitario La Paz
Principal Investigator: Maria Antonia Gómez-Mendieta Hospital Universitario La Paz
  More Information

No publications provided

Responsible Party: Francisco Garcia-Rio, MD, Hospital Universitario La Paz Identifier: NCT01037387     History of Changes
Other Study ID Numbers: HULP PI-825
Study First Received: December 22, 2009
Last Updated: April 1, 2013
Health Authority: Spain: Comité Ético de Investigación Clínica

Additional relevant MeSH terms:
Lung Diseases
Lung Diseases, Obstructive
Pulmonary Disease, Chronic Obstructive
Respiratory Tract Diseases
Bronchodilator Agents
Anti-Asthmatic Agents
Autonomic Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Respiratory System Agents
Therapeutic Uses processed this record on November 20, 2014